姓名 马英
职称
讲师
所在部门
讲师
研究方向
新型抗肿瘤药物研究

办公室
药学院A楼402
办公电话


电子邮箱
maying@tmu.edu.cn

教育背景

2005.10-2009.06 天津理工大学药学专业获学士学位
2010.09-2015.07 天津医科大学药理学专业获博士学位

工作经历

2015.07- 讲师，药学院，天津医科大学

研究成果（本人具有代表性的论著、论文及主持的科研项目）

论文

1.Sun Y-Z, Chen X-B, Wang R-R, Li W-Y, Ma Y^*. Exploring the effect of N308D mutation on protein tyrosine phosphatase-2 cause gain-of-function activity by a molecular dynamics study[J]. Journal of Cellular Biochemistry. 2019;120(4):5949-61.
2.Wei-Ya L, Yu-Qing D, Yang-Chun M, Xin-Hua L, Ying M^*, Wang R-L^*. Exploring the cause of the inhibitor 4AX attaching to binding site disrupting protein tyrosine phosphatase 4A1 trimerization by molecular dynamic simulation[J]. Journal of Biomolecular Structure and Dynamics. 2019:1-12.
3.Wang R-R, Ma Y^#, Du S, Li W-Y, Sun Y-Z, Zhou H, et al. Exploring the reason for increased activity of SHP2 caused by D61Y mutation through molecular dynamics[J]. Comput Biol Chem. 2019;78:133-43.
4.Ma Y, Li H-L, Chen X-B, Jin W-Y, Zhou H, Ma Y^*, et al. 3D QSAR Pharmacophore Based Virtual Screening for Identification of Potential Inhibitors for CDC25B[J]. Comput Biol Chem. 2018;73:1-12.
5.Jin W-Y, Ma Y^#,*, Li W-Y, Li H-L, Wang R-L*. Scaffold-based novel SHP2 allosteric inhibitors design using Receptor-Ligand pharmacophore model, virtual screening and molecular dynamics[J]. Comput Biol Chem. 2018;73:179-88.
6.Li W-Y, Wei H-Y, Sun Y-Z, Zhou H, Ma Y^*, Wang R-L^*. Exploring the effect of E76K mutation on SHP2 cause gain-of-function activity by a molecular dynamics study[J]. Journal of Cellular Biochemistry. 2018;119(12):9941-56.
7.Zhu Y^#, Han Y^#, Ma Y^#,Yang P. ADME/toxicity prediction and antitumor activity of novel nitrogenous heterocyclic compounds designed by computer targeting of alkylglycerone phosphate synthase[J]. Oncol Lett. 2018.
8.Liu X, Jing Z, Jia W-Q, Wang S-Q,Ma Y^*, Xu W-R, et al. Identification of novel PPARα/γ dual agonists by virtual screening, ADMET prediction and molecular dynamics simulations[J]. Journal of Biomolecular Structure and Dynamics. 2017;36(11):2988-3002.
9.Li H-L, Ma Y^#,*, Zheng C-J, Jin W-Y, Liu W-S, Wang R-L^*. Exploring the effect of D61G mutation on SHP2 cause gain of function activity by a molecular dynamics study[J]. Journal of Biomolecular Structure and Dynamics. 2017;36(14):3856-68.
10.Ying Ma^#, Hui-Yu Wei^#, Yu-Ze Zhang, Wen-Yan Jin, Hong-Lian Li, Hui Zhou, Xian-Chao Cheng, and Run-Ling Wang*. Synthesis, bioactivity, 3D-QSAR studies of novel dibenzofuran derivatives as PTP-MEG2 inhibitors [J]. Oncotarget, 2017, 8(24); 38466-38481.
11.Hong-Lian Li^#, Ying Ma^#, Ying Ma,Yu Li, Xiu-Bo Chen, Wei-Li Dong, and Run-Ling Wang*.The design of novel inhibitors for treating cancer by targeting CDC25B through disruption of CDC25B-CDK2/Cyclin A interaction using computational approaches [J]. Oncotarget, 2017, 8 (20); 33225-33240.
12.Ying Ma^#, Yuan-Yuan Jin^#, Ye-Liu Wang, Run-Ling Wang*, Xin-Hua Lu, De-Xin Kong, Wei-Ren Xu. The Discovery of a Novel and Selective Inhibitor of PTP1B Over TCPTP: 3D QSAR Pharmacophore Modeling, Virtual Screening, Synthesis, and Biological Evaluation [J]. Chem Biol Drug Des, 2014, 83; 697-709.
13.Yu-Qing Duan^#, Ying Ma^#, Xue-Jiao Wang, Yuan-Yuan Jin, Run-Ling Wang*, Wei-Li Dong, Wei-Ren Xu, De-Xin Kong, Shu-Qing Wang.Design potential selective inhibitors for treating cancer by targeting the Src Homology 2 (SH2) Domain-Containing Phosphatase 2 (Shp2) with core hopping approach [J]. Protein & Peptide Letters, 2014, 21; 556-563.
14.Yuan-Yuan Jin^#, Ying Ma^#, Quan-Xiong Gao, Run-Ling Wang*, Shu-Qing Wang, Wei-Ren Xu. Design of specific inhibitors of the protein tyrosine phosphatase SHP-2 by virtual screening and core hopping method [J]. Molecular Simulation, 2014, 40 (12); 904-911.
15.Ying Ma^#, Su-Xia Sun^#, Xian-Chao Cheng, Shu-Qing Wang,Wei-Li Dong,Run-Ling Wang*,Wei-Ren Xu. Design and Synthesis of Imidazolidine-2,4-Dione Derivatives as Selective Inhibitors by Targeting Protein Tyrosine Phosphatase-1B Over T-Cell Protein Tyrosine Phosphatase [J]. Chem Biol Drug Des, 2013, 82; 595-602.
16.Ying Ma^#, Shu-Qing Wang^#,*, Wei-Ren Xu, Run-Ling Wang*, Kuo-Chen Chou Design Novel Dual Agonists for Treating Type-2 Diabetes by Targeting Peroxisome Proliferator-Activated Receptors with Core Hopping Approach[J].PLoS ONE, 2012, 7( 6): e38546.



科研项目

1.天津市自然科学基金《SHP2变构抑制剂的设计、合成及其活性研究》(18JCQNJC13700)；2018.04-2021.03；主持
2.天津市教委科研计划项目（自然科学）《SHP2变构抑制剂的设计、合成及其活性研究》(2017KJ229) ；2017.10-2020.09；主持
3.天津市自然科学基金重点项目《选择性SHP2突变体D61G、E76K抑制剂研究》(16JCZDJC32500)；2016.04-2019.03；参与
4.国家自然科学基金国际（地区）合作与交流项目， ，《以SHP2 为靶点的抗白血病药物的设计、合成及活性筛选》；2016.1-2018.12；参与
3.国家自然科学基金项目《具有PTP-1B、PPAR-α、PPAR-γ 三重作用的抗糖尿病先导物的设计、合成及活性研究》（**）；2010.1-2012.12；参与
4.国家自然科学基金项目《高选择性蛋白酪氨酸磷酸酶SHP2抑制剂的研究》(**) ；2013.1-2016.12；参与